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Abstract
New therapeutic concepts developed in rodent models should ideally be evaluated in large animal models prior to human
clinical application. COMMD1-deficiency in dogs leads to hepatic copper accumulation and chronic hepatitis representing a
Wilson’s disease like phenotype. Detailed understanding of the pathogenesis and time course of this animal model is
required to test its feasibility as a large animal model for chronic hepatitis. In addition to mouse models, true longitudinal
studies are possible due to the size of these dogs permitting detailed analysis of the sequence of events from initial insult to
final cirrhosis. Therefore, liver biopsies were taken each half year from five new born COMMD1-deficient dogs over a period
of 42 months. Biopsies were used for H&E, reticulin, and rubeanic acid (copper) staining. Immunohistochemistry was
performed on hepatic stellate cell (HSC) activation marker (alpha-smooth muscle actin, a-SMA), proliferation (Ki67),
apoptosis (caspase-3), and bile duct and liver progenitor cell (LPC) markers keratin (K) 19 and 7. Quantitative RT-PCR and
Western Blots were performed on gene products involved in the regenerative and fibrotic pathways. Maximum copper
accumulation was reached at 12 months of age, which coincided with the first signs of hepatitis. HSCs were activated (a-
SMA) from 18 months onwards, with increasing reticulin deposition and hepatocytic proliferation in later stages. Hepatitis
and caspase-3 activity (first noticed at 18 months) increased over time. Both HGF and TGF-b1 gene expression peaked at 24
months, and thereafter decreased gradually. Both STAT3 and c-MET showed an increased time-dependent activation.
Smad2/3 phosphorylation, indicative for fibrogenesis, was present at all time-points. COMMD1-deficient dogs develop
chronic liver disease and cirrhosis comparable to human chronic hepatitis, although at much higher pace. Therefore they
represent a genetically-defined large animal model to test clinical applicability of new therapeutics developed in rodent
models.
Citation: Favier RP, Spee B, Schotanus BA, van den Ingh TSGAM, Fieten H, et al. (2012) COMMD1-Deficient Dogs Accumulate Copper in Hepatocytes and Provide
a Good Model for Chronic Hepatitis and Fibrosis. PLoS ONE 7(8): e42158. doi:10.1371/journal.pone.0042158
Editor: Erica Villa, University of Modena & Reggio Emilia, Italy
Received April 11, 2012; Accepted July 2, 2012; Published August 6, 2012
Copyright:  2012 Favier et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These authors have no support or funding to report.
Competing Interests: The authors have read the journal’s policy and have the following interests: Ted S.G.A.M. van den Ingh is employed by TCCI Consultancy
BV. The dogs in this study received normal non-copper restricted commercial dog food (Nobless, Purina). There are no patents, products in development or
further marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in
the guide for authors.
* E-mail: r.p.favier@uu.nl
Introduction
Chronic hepatic injury activates a general aetiology-indepen-
dent process characterized by liver regeneration and fibrogenesis.
The sequence of events starts with the primary insult, followed by
hepatocyte proliferation and activation of non-parenchymal cells,
including hepatic stellate cells (HSCs), liver progenitor cells (LPCs)
and macrophages, leading to fibrosis, concomitant failure of
regeneration, and finally cirrhosis [1,2].
HSCs are situated in the space of Disse along the sinusoids.
Quiescent HSCs contain vitamin-A loaded lipid droplets. Upon
cytokine-induced activation HSCs rapidly loose the lipid droplets,
increase the expression of alpha-smooth muscle actin (a-SMA),
and secrete extracellular matrix (ECM) components [3–5]. HSCs,
together with other mesenchymal liver cells and hepatocytes,
produce transforming growth factor b (TGF-b) [6]. A transient
increase of TGF-b1 in the liver promotes fibrosis with the
formation of ECM components, and suppresses hepatocyte
proliferation [7]. The hallmark of TGF-b signaling is Smad2/3
phosphorylation [8]. Oppositely, HSCs play an important role in
hepatic regeneration as they secrete growth factors including
hepatocyte growth factor (HGF). HGF is a potent mitogen for
hepatocytes and induces a plethora of other physiological activities
comprising anti-apoptosis, morphogenesis and angiogenesis [9,10].
When mature hepatocytes are extensively damaged or hampered
in their replication, the LPCs become activated [11]. LPCs are
bipotential and can differentiate both into cholangiocytes and
hepatocytes [1,12,13].
Chronic liver disease is a worldwide health problem, which in
later stages leads to ineffective regeneration, fibrosis, cirrhosis and
tumour formation, and can only be solved by organ transplanta-
tion. New therapeutic options like anti-fibrotic strategies, or
growth factor-mediated interventions are being developed in
rodent model studies [2,14]. The step from principle-to-practice,
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however, remains considerable. The availability of a suitable large
animal model with a pathogenesis and pathophysiology of chronic
liver disease comparable to that in man is lacking. The availability
of such a model would greatly enhance the understanding of
possibilities and drawbacks of new clinical interventions. Further-
more it could be tailored to develop effective and safe protocols
prior to clinical application [14]. Recently, canine fibrotic liver
diseases have been demonstrated to be highly comparable to their
human counterparts in both pathophysiological and molecular
mechanisms [13,15]. Comparable pathophysiology itself is not
sufficient to become a model animal. A defined etiology allows for
more standardized experimental conditions. A dog model with a
well-defined genetic aetiology is the Bedlington terrier (BT) which
lacks the COMMD1 protein. The absence of the COMMD1
protein in BT, due to a deletion of exon-2 of the COMMD1 gene,
results in a progressive accumulation of copper in hepatocytes
leading to chronic hepatitis and cirrhosis [16,17]. This canine
disease was discussed as a potential model for human Wilson’s
disease (WD), an autosomal recessive inherited copper storage
disorder due to a reduced or absent ATP7B gene expression
[18,19,20,21]. COMMD1 and ATP7B proteins interact and
ATP7B function and stability are impaired upon COMMD1
depletion [22,23]. These dogs therefore could serve as model for
Wilson’s disease and in general for chronic liver disease leading to
end-stage liver cirrhosis. Because of their size and life-span, the
availability of molecular tools, the possibility and easiness to
approach the liver with comparable procedures as performed in
man, e.g. to take multiple and sequential liver biopsies, combined
with a known genetic aetiology these dogs are potentially well-
suited for evaluation of new protocols aimed at enhancing liver
regeneration and reduction of fibrosis/cirrhosis. A requirement for
an accepted model is that the pathogenesis of the disease is known
in detail and highly comparable to the human pathology.
Therefore we provide a detailed longitudinal analysis of clinical,
clinicopathological, and molecular aspects focusing on regenera-
tive and fibrotic pathways of COMMD1-deficient dogs.
Results
Physical Examination and Blood Examination
During the entire follow-up period dogs showed no abnormal-
ities at physical examination. Serum ALT was significantly
increased at 24, 36, and 42 months of age (2–3-fold), whereas
serum AP significantly increased at 18 and 42 months of age.
During the 42 months follow-up period, bile acids and albumin
remained within reference limits (Table 1).
Histopathological Findings
At six months of age all dogs showed a moderate centrilobular
hepatic copper accumulation; however no evidence of copper
laden Kupffer cells (phagocytosis of copper from destruction of
copper laden hepatocytes) or other evidence of hepatitis was
observed at this stage (Figure 1). At 12 months of age all animals
had extensive copper accumulation diffuse throughout the lobules
and in two animals a mild hepatitis was present. At 18 months all
dogs showed a slight to mild hepatitis. Although there was some
individual variation, the activity of hepatitis progressed to mild and
moderate at older age (.24 months) in all dogs.
Fibrogenesis
a-SMA showed an increasing presence similarly in the
COMMD1-deficient dogs and normal age matched controls
between 6 (grade 0–1) and 18 months (grade 2). Pathologically
increased a-SMA-immunopositivity positivity was seen in all
COMMD1-deficient dogs in the centrilobular areas starting from
18 months of age (Figure 1 & Table 2).
The reticulin stain showed progressive centrilobular fibrosis
starting in one of the five dogs at 24 months of age (Figure 1 &
Table 2) and present in all COMMD1-deficient dogs at 42 months
of age, finally resulting in centro-central bridging fibrosis and
cirrhosis in three of the five animals (at 42 months). Sirius red
staining was similar to reticulin staining (data not shown).
Apoptosis and Regeneration
Active caspase-3 remained undetectable up to 24 months and
became visible in the hepatocytes from 30 months of age until 42
months (Table 3). A 2-fold increased median number of Ki67
positive hepatocytes was seen at 36 and 42 months (Table 3),
particularly in the three dogs with centro-central bridging fibrosis
and cirrhosis, and in the areas with the least copper storage. Both
K7 and K19 stainings showed a doubling (median number) of
LPCs at 30 months of age and further increase later on, but they
showed no differentiation into intermediate cells (Table 3).
Gene-expression Profiling
The mRNA levels of TGF-b1 and both its receptors increased
significantly starting at 24 months and decreased gradually
afterwards (Figure 2A). The increase in relative mRNA levels of
HGF and its receptor c-MET was sharp and strong (15 and 11-
fold, respectively) occurring at 24 months of age in all dogs
(Figure 3A). These levels decreased gradually over time and
returned to basal levels at 36 months of age.
Western Blot Analysis
Western blots were performed at the time points 12 (prior to
elevation of mRNA levels of TGF-b1, HGF and their respective
receptor), 30 (elevated mRNA levels), and 42 (mRNA levels
returned to basal levels) months of age. Smad2/3 was detectable at
all time-points. Phosphorylated Smad2 was present in the
COMMD1-deficient dogs at all time-points (Figure 2B). HGF
was variably present at all measured time-points in COMMD1-
Table 1. Blood examinations.
Parameter
&
Reference
Range
ALT
0–54 U/l
AP
0–73 U/l
Bile acids
0–10 mmol/l
Albumin
26–37 g/L
Age (months)
12 44
(34–75)
73
(66–109)
7
(3–11)
33
(30–34)
18 45
(35–60)
111 *
(91–209)
1
(1–2)
30
(28–32)
24 66 *
(43–257)
115
(61–120)
7
(6–12)
29
(27–31)
30 83 *
(62–153)
87
(68–140)
4
(1–8)
30
(30–32)
36 180
(69–225)
94
(59–153)
2
(0–3)
29
(29–30)
42 112 *
(55–201)
101 *
(72–219)
2
(1–3)
28
(27–30)
ALT: alanine aminotransferase; AP: alkaline phosphatase.
Blood examinations during aging in five COMMD1-deficient dogs. Values are
expressed as median (range).
*significantly increased serum concentration compared with 12 months of age.
doi:10.1371/journal.pone.0042158.t001
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Figure 1. Histological description. COMMD1-deficient dog livers were stained with H&E and RA to assess inflammation and copper accumulation,
respectively, and stained for a-SMA and reticulin (collagen type III) to assess fibrosis. Representative pictures of a COMMD1-deficient dog over a
period of 42 months are shown. Numbers indicate age in months.
doi:10.1371/journal.pone.0042158.g001
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deficient dogs. Phosphorylated c-MET was increased age-depen-
dently as was phosphorylated STAT3 (Figure 3B).
Discussion
We evaluated COMMD1-deficient dogs as a possible large
animal model for chronic hepatitis, in a 42 month lasting
longitudinal study. A clear sequence of events occurred and
explains in molecular terms the histological finding: copper
accumulation, followed by hepatocellular damage, increased
plasma ALT activity, hepatitis, HSC activation and fibrosis and
further progression towards centro-central bridging fibrosis and
cirrhosis. At the latest stages increased HGF proteins and activated
STAT3 proteins were present.
Free copper is highly toxic due to its ability to generate hydroxyl
radicals and it has been demonstrated that hepatocellular
apoptosis is triggered by copper-induced cell damage [24,25,26].
Signs of regeneration appeared when the inflammatory process
had progressed. This was mainly associated with hepatocytic
regeneration shown by Ki67 immunostaining. LPC activation,
reflected by non-cholangiocytic K19 immunostaining, was also
present. In acute hepatitis LPCs differentiate through intermediate
hepatocytes into hepatocytes within one week after the insult [27].
The fact that no intermediate hepatocytes were seen near the
activated LPCs in the COMMD1-deficient dogs indicates a minor
contribution of these cells to liver regeneration in this stage of
hepatitis. The slow onset of disease and regenerative capacity of
hepatocytes may explain that the endogenous LPCs do not
contribute to the regeneration process in this model. One
important multifunctional cytokine during liver regeneration is
HGF [9,10]. In this study, mRNA-expressions of HGF and its
receptor c-MET peaked at 24 months of age. This coincided with
hepatic stellate cell activation (a-SMA), and the expression of
TGF-b1 and its receptors. Although HGF and c-MET expression
were temporarily present, HGF, c-MET activation, and the down-
stream time-dependent increase in phospho-STAT3 indicated a
continuous activation of the regenerative pathway. High HGF
protein levels at 42 months, most likely from an extra–hepatic
source, stimulated STAT3 activation but cannot rule out increased
inflammatory signaling via e.g. the IL-6 receptor towards STAT3
phosphorylation.
TGF-b1 signalling components (at mRNA and activated protein
level) increased transiently from 24 months and coincided
expectedly with an increased fibrosis (reticulin staining). The
presence of pSMAD2/3 already at 12 months remains unex-
plained.
Until now COMMD1-deficient Bedlington terriers have been
the best described dog model for hepatic copper toxicosis. Copper
storage in COMMD1-deficient dogs causes chronic hepatitis,
fibrosis and cirrhosis causing hepatic failure, portal hypertension,
ascites, portosystemic collateral circulation, and hepatic enceph-
alopathy. Therewith all features of chronic hepatitis and cirrhosis,
not only copper-associated, are displayed. This experimentally
reproducible autosomal recessive genetic disease may thus serve as
an appropriate large animal model for chronic hepatitis and
cirrhosis in man. Our study adds to the understanding of the
sequence of pathophysiological events occurring in copper-
associated hepatitis in COMMD1-deficient dogs and agrees with
a semi-longitudinal study performed in ATP7B2/2 mice [28].
COMMD1 mutations have so far not been associated with
unexplained copper storage diseases in man [29,30]. Although
COMMD1 function remains puzzling [31], the major effects of its
absence in the dog model seem to be impaired ATP7B-mediated
copper export from the hepatocytes [22]. The COMMD1-
deficient dog model is thus not the exact copy of Wilson’s disease,
but shows all relevant features of human chronic hepatitis. This is
the first well-defined large animal model of chronic hepatitis. We
anticipate that it may provide an important instrument for the
evaluation of future regenerative and anti-fibrotic therapies in a
preclinical model and helps to close the gap between commonly
used rodent models and human pathology.
In December 2011 a PlosOne paper described copper
accumulation in liver-specific COMMD1 KO mouse [32] and
confirmed the siRNA-based conclusion that COMMD1 plays an
essential role in hepatic copper homeostasis [20,33]. Surprisingly,
these mice did not develop an obvious liver pathology under
excessive copper diet. This clearly underscores the importance of
Table 2. Fibrosis.
Age
(months) 6 12 18 24 30 36 42
a-SMA
grading (0–4)
1
(2)
2
(1–2)
2
(2–2.5)
3
(2–4)
3
(3–4)
4
(2–4)
3
(2–4)
p-value 2 0.15 0.048 0.057 0.053 0.054 0.057
Reticulin
grading (0–3)
0
(2)
1
(0–1)
0
(0–1)
1
(0–2.5)
0
(0–2.5)
2.5
(0–3)
2
(1–3)
p-value 2 0.15 1 0.17 0.37 0.17 0.058
Fibrosis scoring: a-SMA (hepatic stellate cell activation) and reticulin grading
(collagen type III) in five COMMD1-deficient dogs in a time-dependent copper-
induced hepatitis. Data are presented as median (range).
a-SMA grading; 0: no staining of HSCs; 1: a few positive HSCs; 2: diffuse staining
of HSCs; 3: mild increased staining of HSCs; 4: marked increased staining of HSC
and compared with age matches normal controls.
Reticulin grading; grade 0: normal, grade 1: local mild centrilobular increase,
grade 2: multifocal mild to moderate centrilobular increase, grade 3: moderate
increase with centro-central bridging or nodular transformation. The
uncorrected p-values for comparison of each time point with 6 months of age
are reported in the table. No significant differences are present when correcting
these p-values for the number of tests.
doi:10.1371/journal.pone.0042158.t002
Table 3. Apoptosis and regeneration.
Age
(months) 6 12 18 24 30 36 42
Casp3 0
(2)
0
(2)
0
(2)
0
(2)
0.1
(0–3)
0.1
(0–1.1)
0.1
(0–0.1)
p-value 2 NA NA NA 0.15 0.17 0.35
Ki67 0.9
(0.6–2.9)
0.8
(0.4–1.1)
1.1
(0.7–2.0)
0.5
(0.3–1.3)
0.7
(0.1–1.0)
2.3
(0.1–4.4)
2.1
(1–4.6)
p-value 2 0.79 0.88 0.25 0.13 0.88 0.5
K19 1.9
(1.2–3.2)
2.5
(1–3.3)
3.2
(2.7–3.4)
1.8
(1.5–3.3)
3.7
(2.5–5.3)
3.6
(2.8–7.4)
5.2
(4–9.6)
p-value 2 0.10 0.063 0.58 0.058 0.063 0.125
NA: not available.
Number of (active) caspase-3 (Casp3) positive hepatocytes per 10-times
objective (manual count), number of Ki67 positive hepatocytes per 10-times
objective (manual count), and number of K19 positive cells in the limiting plate
per portal area in five COMMD1-deficient dogs in a time-dependent copper-
induced hepatitis. Data are presented as median (range).
The uncorrected p-values for comparison of each time point with 6 months of
age are reported in the table. No significant differences are present when
correcting these p-values for the number of tests.
doi:10.1371/journal.pone.0042158.t003
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Figure 2. TGF-b1 pathway. (A) Gene-expression profiling. Interaction plots of Q-PCR data of important mediators of fibrogenesis in a time-
dependent copper-induced hepatitis in five COMMD1-deficient dogs. Q-PCR results were normalized against the expression of six control dogs (one
to three years of age). Linear mixed-effect modeling was used; * significant difference corrected for multiple testing. (B) Western blot analysis on the
activation of TGF-beta signalling (total Smad2 and phosphorylated Smad2 (Ser727)) of five COMMD1-deficient dogs at 12, 30, and 42 months. b-actin
(ACTB) served as loading control.
doi:10.1371/journal.pone.0042158.g002
Figure 3. HGF pathway. (A) Gene-expression profiling. Interaction plots of Q-PCR data of important mediators of regeneration in a time-
dependent copper-induced hepatitis in five COMMD1-deficient dogs. Q-PCR results were normalized against the expression of six control dogs (one
to three years of age). Linear mixed-effect modeling was used; * significant difference corrected for multiple testing. (B) Western blot analysis on the
activation HGF-signalling (HGF, phosphorylated c-Met, (phosphorylated) STAT3) of five COMMD1-deficient dogs at 12, 30, and 42 months. b-actin
(ACTB) served as loading control.
doi:10.1371/journal.pone.0042158.g003
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this canine model as a long-term model for (therapeutic
interventions into) chronic hepatitis.
Materials and Methods
Animals
Five new born COMMD1-deficient dogs with confirmed
COMMD1 status (two males, three females) were used for
longitudinal follow-up [34]. Dogs were examined every six months
until the age of 42 months. At each occasion the clinical symptoms
were scored, physical and blood examinations were performed,
and liver biopsies were taken. Dogs were housed individually and
received normal non-copper restricted commercial dog food
(Noblesse, Purina), once a day and water ad libitum. The
procedures were approved by Utrecht University’s Ethical
Committee, as required under Dutch legislation (ID
2007.III.06.080).
Blood Examinations
Serum alanine aminotransferase (ALT), alkaline phosphatase
(AP), bile acids, and albumin were determined using a DXC-600
Beckman (Beckman Coulter, Woerden, the Netherlands). Refer-
ence ranges for ALT, AP, bile acids, and albumin are 0–54 U/l,
0–73 U/l, 0–10 mmol/l, and 26–37 g/L, respectively.
Liver Tissue Sampling and Histopathology
Liver biopsies (five per dog per time-point) were obtained using
a 14G Menghini needle [35]. Two biopsies were formalin-fixed
and paraffin-embedded, and 4 mm thick paraffin sections were
stained with haematoxylin and eosin (H&E), rubeanic acid (RA)
for copper quantification, reticulin (Gordon and Sweet), and Sirius
red. Hepatitis and fibrosis scoring were performed by one board-
certified veterinary pathologist (TvdI) according to the WSAVA
classification [36]. Copper accumulation (RA) was evaluated semi-
quantitatively using a scale from 0 to 5 as previously described
[37], and localization within the liver lobule was assessed. Three
biopsies were fixed in RNAlater (Ambion, Austin, TX, USA) for a
maximum of 24 hours and stored at 270uC.
Immunohistochemistry
Alpha-smooth muscle actin (a-SMA), activated caspase-3
(Casp3), proliferation marker Ki67, Keratin 7 (K7), and Keratin
19 (K19) were stained as described elsewhere with slight
modifications [5,38]. The antibodies used for IHC are described
in Table S1. Three mm sections were mounted on poly-L lysine
coated slides and stored for a maximum of 48 hours at room
temperature (RT). Sections were deparaffinised followed by
antigen retrieval (AR). Enzymatic AR was performed with
proteinase K (DAKO, Glostrup, Danmark) for 40 minutes (K7)
or 15 minutes (K19). AR for Ki67 was achieved in 10 mM citric
acid buffer (pH 6) for 15 minutes in a microwave. Activated casp3
and a-SMA staining needed no AR. Endogenous peroxidase and
unspecific binding were blocked in 0.3% H2O2 and 10% non-
immune goat serum for 30 min, respectively. After application of
the primary antibody over-night (Casp3 and K7) or 1 h at RT (a-
SMA, Ki67, and K19), slides were washed in PBS and incubated
with the appropriate secondary antibody (Envision (DAKO) HRP-
labeled polymer, anti-mouse or -rabbit) for 45 minutes at RT.
After washing staining was detected using 3-39-diaminobenzidine
and counterstained with 10% Mayer’s haematoxylin.
a-SMA grading was performed as follows; 0: no staining of
HSCs; 1: a few positive HSCs; 2: diffuse staining of HSCs; 3: mild
increased staining of HSCs; 4: marked increased staining of HSCs.
Results were compared with normal aged matched controls. The
quantity of liver tissues from two needle biopsies was equal at all
time points and in all animals; therefore both Ki67 and Casp3
were expressed as the number of positive hepatocytes per slide.
K19 and K7 were graded as the number of positive cells in the
limiting plate per portal area, either solitary or as small groups.
RNA Isolation and Quantitative RT-PCR (q-PCR)
RNA was isolated from RNAlater (Ambion, Austin, TX, USA)
fixed biopsies, using Qiagen RNeasy Mini Kit (Qiagen, Leusden,
the Netherlands). RNA quality was analysed with the Agilent
BioAnalyzer 2100 (Agilent, Palo Alto, CA, USA). A SYBR green
I-based Q-PCR was performed on TFG-b1, TGF-b receptor type
I (TGF-bR1), TGF-b receptor type II (TGF-bR2), hepatocyte
growth factor (HGF), and c-MET protooncogene (c-MET) (Table
S2) [15]. Normalisation was performed using four reference-genes
(glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxan-
thine phosphoribosyl transferase (HPRT), ribosomal protein S5
(RPS5) and S19 (RPS19)) [39]. Q-PCR results were related to the
expression of six clinically and histologically determined healthy
control dogs (one to three years of age). Minus RT and water
controls remained negative.
Western Blot Analysis
Liver biopsies were lysed in RIPA buffer containing
50 mM Tris–HCl, 150 mM NaCl, 1% NP-40, 0.25% sodium
deoxycholate, 1 mM EDTA, 1 mM sodium orthovanadate, 1 mg/
ml aprotinin, and 1 mM PMSF. Extracted protein was quantified
using a Lowry based assay (DC Protein Assay, Bio-Rad,
Veenendaal, the Netherlands). To detect HGF, phospho-c-
MET, (phospho-)STAT3 and (phospho-)Smad2/3 protein levels,
7.5 mg protein was denatured for 3 minutes at 95uC, subsequently
run on a Criterion Tris-HCl polyacrylamide gel (Bio-Rad),
transferred to Hybond-C nitrocellulose membranes (Amersham
Biosciences, Roosendaal, the Netherlands) and blocked with the
ECL Advance Western Blotting Detection Kit (Amersham, Little
Chalfont, UK) or with non-fat dry milk (HGF). The blots were
incubated overnight at 4uC with the appropriate primary
antibodies (Table S3) and subsequently incubated with HRP-
conjugated anti-mouse antibodies (R&D Systems Europe, Abing-
don, UK; dilution 1:20,000) or HRP-conjugated anti-rabbit
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA;
dilution 1:20,000). All secondary antibodies were incubated for 1
hour at RT. Luminescence induced by the ECL Advanced
Western Blotting Detection Kit (Amersham) was measured with a
ChemiDoc XRS Imager (BioRad) and analyzed with provided
software (Quantity-One 4.6.5).
Statistical Analysis
Statistical analysis was performed in R (version 2.11.1) [40]. Q-
PCR data and results of blood examination were analyzed using
linear mixed-effect modeling with the R package ‘‘nlme’’. When
necessary, the outcome variables were transformed by their
natural logarithm in order to fulfill the criteria of normality and
constant variance. Restricted maximum likelihood method was
used to estimate the best fitting model with a random intercept, a
random slope, or both based on Akaike’s information criteria.
Maximum likelihood was used to estimate the fixed effect of the
time in months (included in the model as a factor). Residuals were
checked for normality and constancy of variance. The Wilcoxon
signed rank test with continuity correction was performed for
comparisons of all time points with the reference time point
(6 months) for differences in immunohistochemical data. Uncor-
rected p-values were reported in Table 2 and 3. P-values were
A Dog Model for Chronic Hepatitis and Fibrosis
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considered significant, when the p-value times the number of
comparisons was ,0.05.
Supporting Information
Table S1 Used antibodies in immunohistochemical experi-
ments.
(DOC)
Table S2 Nucleotide Sequences of dog specific primers for
Quantitative Real-Time PCR.
(DOC)
Table S3 Used antibodies in Western blot experiments.
(DOC)
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